All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
APOLLOE4
The purpose of this study is to determine if the study drug called ALZ-801 is safe, if it is well tolerated, and if it is effective in treating AD. It is a twice a day oral medication that is taken with meals.
Cassava RefocusALZ
The purpose of this study is to learn more about the use of the study drug, simufilam, for the treatment of Alzheimer’s disease. We want to test that it is safe and to find out whether it can slow down the advance of Alzheimer’s disease.
Alector (FTD)
This project is being done to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).
TREAT MS: Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREATMS) Trial
The purpose of this research is to identify the most appropriate treatment strategy for people with multiple sclerosis (MS), especially shortly after diagnosis when it may be most possible to increase a patient’s chance for preventing longer-term disability.
EXCHANGE: Safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study
In this study we want to find out how safe Siponimod is and how well you tolerate to the drug. The results of this study will help doctors decide if and when to switch patients from other MS medicines (also known as disease modifying therapies or DMTs) to Siponimod.
Celegene: A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod(RPC-1063)
The purpose of this study is to learn about changes in cognition that happen while taking the study medication RPC-1063, also known as Ozanimod. Everyone that participates in this study will receive Ozanimod, which is an experimental drug. “Experimental” means that the study drug is still being tested for safety and effectiveness and is not approved for sale in the United States by the Food and Drug Administration (FDA).
Using Art to Increase Health Literacy of Physical Activity in Patients With Parkinson Disease
The purpose of this program is to use creative art (visual or movement based) to increase health literacy in the area of physical activity recommendations for individuals who have Parkinson’s Disease.
Utilization of Target Ranges to Treat Patients With Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph (PKG) Compared to Standard of Care Assessment (TARGET-PD)
The purpose of this project is to evaluate whether patients with Parkinson’s disease who are managed with standard of care and the aid of target ranges reported on the PKG have improved Parkinson’s disease symptoms and outcomes compared to patients treated only with standard of care.
A 52-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson’s Disease.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI (subcutaneous injection) for 24 hours daily for up to 52 weeks.
A Randomized, Double-Blind, Placebo-Controlled Trial of Urate Elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson’s Disease
To determine whether oral inosine dosed to moderately elevate serum urate over 2 years slows clinical decline in early Parkinson’s Disease.
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants w/ Parkinson’s Disease
The primary objective of this two-cohort study is to assess the safety and tolerability of the daily oral administration of Nilotinib or placebo in participants with moderate to advanced PD (Cohort 1) and in participants with early/de novo PD (Cohort 2). Participants in Cohort 2 will be treated with the selected dose determined in Cohort 1 or matching placebo. Cohort 1 will be treated with Nilotinib 150mg, 300mg, or matching placebo.
SPARK-PD - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BIIB054 in Subjects With Parkinson’s Disease
The primary objective of this study is to evaluate the dose-related safety of BIIB054. There is a placebo-controlled treatment period (48 weeks) followed by a dose-blinded active treatment (48 weeks).
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of 36 Weeks Treatment With NLY01 in Early-Stage Parkinson’s Disease
Primary Investigator: Karen Blindauer, MD
Structural and Functional Connectivity Changes in the Brain in Response to Diagnostic Nerve Blocks in Stroke Survivors
Identify changes in brain functional connectivity associated with diagnostic nerve blocks (DNB) to relieve spasticity in stroke survivors.
IPSEN Abolish: Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)
Observational study to assess the longitudinal attainment of person centered and function related goals after one or more abobotulinum toxin A (aboBoNT-A) injections in the lower limb using the cumulated Goal Attainment Scaling -Leg (GASleg) T score in a real life clinical setting.
Merz: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)
To test the safety and efficacy of NT 201 (Xeomin) for treating lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
SleepSmart: The Sleep for Stroke Management and Recovery Trial
Designed to evaluate ischemic stroke patients or patients with transient ischemic attack (TIA) for obstructive sleep apnea. Patients who qualify, will help assess whether continuous positive airway pressure (CPAP) for obstructive sleep apnea, after stroke, helps with recovery or helps prevent another stroke.
ARCADIA: Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke
A randomized, controlled trial of anticoagulation with Apixaban versus Aspirin for patients with embolic stroke of undetermined source, or ESUS, and evidence of atrial cardiopathy.
Progesterone for Traumatic Brain Injury; Experimental Clinical Treatment (PROTECT)
Keywords
TBI, Exception from Informed Consent
Image-Based Predictions of Hemodynamics
The research studies blood flow in aneurysm for the selection of treatment. (NIH RO1: HL115267)
Stroke Recruitment Database
The database is designed specifically to serve as a screening and recruitment tool for stroke researchers in the greater Milwaukee Area, matching stroke survivors willing to contribute to science as research participants with study coordinators seeking to populate their studies with individuals meeting their particular inclusion/exclusion criteria.